UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa

Microbiology (Society for General Microbiology), 2001-10, Vol.147 (Pt 10), p.2659-2669

2001

Volltextzugriff (PDF)

LB0004 EFFICACY AND SAFETY OF SECUKINUMAB IN ENTHESITIS-RELATED ARTHRITIS AND JUVENILE PSORIATIC ARTHRITIS: PRIMARY RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREATMENT WITHDRAWAL, PHASE 3 STUDY (JUNIPERA)

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.201-202

2021

Volltextzugriff (PDF)

OP0283 Microrna 125A-5P has Increased Expression in Active Systemic Juvenile Idiopathic Arthritis and is an Essential Modulator of Regulatory Macrophage Phenotypes in Vitro

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.179-180

2015

Volltextzugriff (PDF)

Secretion of the Toxin ExoU Is a Marker for Highly Virulent Pseudomonas aeruginosa Isolates Obtained from Patients with Hospital-Acquired Pneumonia

The Journal of infectious diseases, 2003-12, Vol.188 (11), p.1695-1706

2003

Volltextzugriff (PDF)

OP0012 Microrna Associated with Active Systemic Juvenile Idiopathic Arthritis Regulate CD163 Expression in Polarized Macrophages through Two Distinct Mechanisms

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.57-57

2016

Volltextzugriff (PDF)

High levels of interferon-gamma (IFNγ) in macrophage activation syndrome (MAS) and CXCL9 levels as a biomarker for IFNγ production in MAS

Pediatric rheumatology online journal, 2015-09, Vol.13 (S1), p.O84-O84, Article O84

2015

Volltextzugriff (PDF)

POS0756 IDENTIFICATION OF GENETIC RISK FACTORS FOR JUVENILE IDIOPATHIC ARTHRITIS-ASSOCIATED UVEITIS

Annals of the rheumatic diseases, 2024-06, Vol.83 (Suppl 1), p.1164-1164

2024

Volltextzugriff (PDF)

The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS)

Arthritis & rheumatology (Hoboken, N.J.), 2023-10, Vol.75 (10), p.1714-1732

2023

Volltextzugriff (PDF)

OP0166 LONG-TERM FOLLOW-UP OF PATIENTS ADMINISTERED EMAPALUMAB, AN ANTI–INTERFERON-Γ MONOCLONAL ANTIBODY, TO TREAT MACROPHAGE ACTIVATION SYNDROME (MAS) SECONDARY TO SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA)

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.110-111

2023

Volltextzugriff (PDF)

Differential infection of mononuclear phagocytes by Francisella tularensis: role of the macrophage mannose receptor

Journal of leukocyte biology, 2006-09, Vol.80 (3), p.563-571

2006

Volltextzugriff (PDF)

POS0278 EFFICACY AND SAFETY OF SECUKINUMAB IN JUVENILE IDIOPATHIC ARTHRITIS: INTERIM RESULTS FROM THE EXTENSION OF THE JUNIPERA TRIAL

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.379-380

2023

Volltextzugriff (PDF)

POS0076 S100A8/A9 AND S100A12 AS POTENTIAL PREDICTIVE BIOMARKERS OF ABATACEPT RESPONSE IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.245-246

2021

Volltextzugriff (PDF)

P127 Lung disease in systemic JIA: an emerging problem linked with young age and anti-IL-1/IL-6

Annals of the rheumatic diseases, 2019-03, Vol.78 (Suppl 1), p.A57

2019

Volltextzugriff (PDF)

Delivering clinical trials at home: protocol, design and implementation of a direct-to-family paediatric lupus trial

Lupus science & medicine, 2021-05, Vol.8 (1), p.e000494

2021

Volltextzugriff (PDF)

Morbidity associated with Pseudomonas aeruginosa bloodstream infections

Diagnostic microbiology and infectious disease, 2009-07, Vol.64 (3), p.311-319

2009

Volltextzugriff (PDF)

Type III Secretion Phenotypes of Pseudomonas aeruginosa Strains Change during Infection of Individuals with Cystic Fibrosis

Journal of Clinical Microbiology, 2004-11, Vol.42 (11), p.5229-5237

2004

Volltextzugriff (PDF)

High levels of interferon-gamma and CXCL9 levels as a biomarker for IFN[gamma] production in MAS

Pediatric rheumatology online journal, 2015-09, Vol.13 (Suppl 1)

2015

Volltextzugriff (PDF)

High levels of interferon-gamma (IFN[gamma]) in macrophage activation syndrome (MAS) and CXCL9 levels as a biomarker for IFN[gamma] production in MAS

Pediatric rheumatology online journal, 2015-09, Vol.13 (Suppl 1)

2015

Volltextzugriff (PDF)

Mevalonate kinase deficiency: current perspectives

Application of clinical genetics, 2016-07, Vol.2016 (Issue 1), p.101-110

2016

Volltextzugriff (PDF)

American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 2

Arthritis & rheumatology (Hoboken, N.J.), 2021-04, Vol.73 (4), p.e13-e29

2021

Volltextzugriff (PDF)

American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 1

Arthritis & rheumatology (Hoboken, N.J.), 2020-11, Vol.72 (11), p.1791-1805

2020

Volltextzugriff (PDF)

American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 3

Arthritis & rheumatology (Hoboken, N.J.), 2022-04, Vol.74 (4), p.e1-e20

2022

Volltextzugriff (PDF)

A novel STING1 variant causes a recessive form of STING-associated vasculopathy with onset in infancy (SAVI)

Journal of allergy and clinical immunology, 2020-11, Vol.146 (5), p.1204-1208.e6

2020

Volltextzugriff (PDF)

Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial

Annals of the rheumatic diseases, 2023-01, Vol.82 (1), p.154-160

2023

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(44)
Mit Volltextzugriff
(36)

Publikationsform

Sprache

Englisch
(49)
Deutsch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa

LB0004 EFFICACY AND SAFETY OF SECUKINUMAB IN ENTHESITIS-RELATED ARTHRITIS AND JUVENILE PSORIATIC ARTHRITIS: PRIMARY RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREATMENT WITHDRAWAL, PHASE 3 STUDY (JUNIPERA)

OP0283 Microrna 125A-5P has Increased Expression in Active Systemic Juvenile Idiopathic Arthritis and is an Essential Modulator of Regulatory Macrophage Phenotypes in Vitro

Secretion of the Toxin ExoU Is a Marker for Highly Virulent Pseudomonas aeruginosa Isolates Obtained from Patients with Hospital-Acquired Pneumonia

OP0012 Microrna Associated with Active Systemic Juvenile Idiopathic Arthritis Regulate CD163 Expression in Polarized Macrophages through Two Distinct Mechanisms

The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS)

High levels of interferon-gamma (IFNγ) in macrophage activation syndrome (MAS) and CXCL9 levels as a biomarker for IFNγ production in MAS

POS0756 IDENTIFICATION OF GENETIC RISK FACTORS FOR JUVENILE IDIOPATHIC ARTHRITIS-ASSOCIATED UVEITIS

The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS)

OP0166 LONG-TERM FOLLOW-UP OF PATIENTS ADMINISTERED EMAPALUMAB, AN ANTI–INTERFERON-Γ MONOCLONAL ANTIBODY, TO TREAT MACROPHAGE ACTIVATION SYNDROME (MAS) SECONDARY TO SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA)

Differential infection of mononuclear phagocytes by Francisella tularensis: role of the macrophage mannose receptor

POS0278 EFFICACY AND SAFETY OF SECUKINUMAB IN JUVENILE IDIOPATHIC ARTHRITIS: INTERIM RESULTS FROM THE EXTENSION OF THE JUNIPERA TRIAL

POS0076 S100A8/A9 AND S100A12 AS POTENTIAL PREDICTIVE BIOMARKERS OF ABATACEPT RESPONSE IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS

P127 Lung disease in systemic JIA: an emerging problem linked with young age and anti-IL-1/IL-6

Delivering clinical trials at home: protocol, design and implementation of a direct-to-family paediatric lupus trial

Morbidity associated with Pseudomonas aeruginosa bloodstream infections

Type III Secretion Phenotypes of Pseudomonas aeruginosa Strains Change during Infection of Individuals with Cystic Fibrosis

High levels of interferon-gamma and CXCL9 levels as a biomarker for IFN[gamma] production in MAS

High levels of interferon-gamma (IFN[gamma]) in macrophage activation syndrome (MAS) and CXCL9 levels as a biomarker for IFN[gamma] production in MAS

Mevalonate kinase deficiency: current perspectives

American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 2

American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 1

American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 3

A novel STING1 variant causes a recessive form of STING-associated vasculopathy with onset in infancy (SAVI)

Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial

Suchergebnisse filtern